Screener
Pulse Biosciences, Inc. PLSE Business Segments — Cost Of Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pulse Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Pulse Biosciences, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:23 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026288
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue | $434 | — | $835 | — |
| Adjusted cost of product revenue1 | 245 | — | 571 | — |
| Cross platform research and engineering2 | 6,078 | 4,585 | 11,258 | 8,535 |
| R&D manufacturing and engineering3 | 3,201 | 2,941 | 5,550 | 4,736 |
| Clinical and regulatory4 | 5,127 | 2,183 | 8,387 | 3,943 |
| General and administrative5 | 4,548 | 2,742 | 8,490 | 5,461 |
| Sales and marketing6 | 1,279 | 2,362 | 3,607 | 4,218 |
| Other segment items7 | 5,228 | 5,462 | 7,394 | 11,426 |
Document
FAQ
- What is Pulse Biosciences, Inc.'s business segments — cost of revenue?
- Pulse Biosciences, Inc. (PLSE) reported business segments — cost of revenue of $245K in Q2 2026.
- What does business segments — cost of revenue mean?
- This includes the direct costs attributable to the production and delivery of the company's products or services. Monitoring this metric is essential for evaluating the direct profitability of the company's core business operations before accounting for operating expenses.
Ask your AI about Pulse Biosciences, Inc.'s business segments — cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude